Clinical Trial: Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Study Status: Completed
Recruit Status: RECRUITING
Condition: Unresectable Metastatic Colorectal Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects With Unresectable
Brief Summary:
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably.The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given in combination with Fluorouracil, Folinic Acid, and Bevacizumab to adult participants to treat unresctable metastatic colorectal cancer.ABBV-400 is an investigational drug being developed for the treatment of unresectable metastatic colorectal cancer.Fluorouracil, folinic acid, and bevacizumab is an drug approved…
Read more